Skip to main content
SpringerLink
Log in

Head Shot!

  • Chapter
  • First Online:
Immunohematology, Transfusion Medicine, Hemostasis, and Cellular Therapy

  • 524 Accesses

Abstract

Knowing treatment modalities to reverse novel anticoagulants can be key to saving the life of an individual who develops a bleeding complication. Solve it!

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gehrie E, Tormey C. Novel oral anticoagulants. Efficacy, laboratory measurement, and approaches to emergent reversal. Arch Pathol Lab Med. 2015;139:687–92.

    Article  CAS  PubMed  Google Scholar 

  2. Ikeda K, Tachibana H. Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation. J Arrhythm. 2016;32(1):42–50.

    Article  PubMed  Google Scholar 

  3. Maier CL, Asbury WH, Duncan A, Robbins A, Ingle A, Webb A, Stowell SR, Roback JD. Using an old test for new tricks: measuring direct oral anti-Xa drug levels by conventional heparin-calibrated anti-Xa assay. Am J Hematol. 2019;94(5):E132–4.

    Article  PubMed  PubMed Central  Google Scholar 

  4. ANDEXXA®. Prescribing information. South San Francisco, CA: Portola Pharmaceuticals; 2020.

    Google Scholar 

  5. Momin JH, Hughes GJ. Andexanet alfa (Andexxa®) for the reversal of direct oral anticoagulants. P &T. 2019;44(9):530–49.

    Google Scholar 

  6. Hu TY, Vaidya VR, Asirvatham SJ. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016;12:35–44.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. XARELTO®. Prescribing information. Titusville, NJ: Janssen Pharmaceuticals; 2020.

    Google Scholar 

  8. ELIQUIS®. Prescribing information. Princeton, NJ: Bristol-Meyers Squibb; 2019.

    Google Scholar 

  9. BEVYXXA®. Prescribing information. South San Francisco, CA: Portola Pharmaceuticals; 2019.

    Google Scholar 

  10. SAVAYSA®. Prescribing information. Basking Ridge, NJ: Daiicho Sankyo; 2020.

    Google Scholar 

  11. Kcentra®. Prescribing information. Kankakee, IL: CSL Behring, LLC; 2018.

    Google Scholar 

  12. Galassi A, Podda G, Monciino P, Stucchi A, Del Nero A, Cozzolino M. Dabigatran overload in acute kidney injury: haemodialysis or idarucizumab? a case report and proposal for a decisional algorithm. Clin Kidney J. 2020;14(2):712–4.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Milling TJ, Kaatz S. Preclinical and clinical data for factor Xa and “universal” reversal agents. Am J Emerg Med. 2016;34(11 Suppl):39–45.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Ansell J, Laulicht B, Bakhru SH, Burnett A, Jiang X, Chen L, et al. Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics and reversal of anticoagulants. Blood. 2021;137(1):115–25.

    Article  CAS  PubMed  Google Scholar 

  15. Beulens JW, Booth SL, van den Heuvel EG, Stoecklin E, Baka A, Vermeer C. The role of menaquinones (vitamin K2) in human health. Br J Nutr. 2013;110(8):1357–68.

    Article  CAS  PubMed  Google Scholar 

Further Reading

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, NYU Lagone Health, Mineola, NY, USA

    Mark T. Friedman

  2. Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD, USA

    Kamille A. West

  3. Department of Pediatrics, Northwell Health System, Great Neck, NY, USA

    Peyman Bizargity

  4. Department of Pathology, Children’s Hospital Colorado, Aurora, CO, USA

    Kyle Annen

  5. Department of Pathology, Northwell Health System, Greenvale, NY, USA

    H. Deniz Gur

  6. Department of Pathology, NYU Langone Health, New York, NY, USA

    Timothy Hilbert

Authors
  1. Mark T. Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kamille A. West
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peyman Bizargity
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kyle Annen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Deniz Gur
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Timothy Hilbert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark T. Friedman .

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Friedman, M.T., West, K.A., Bizargity, P., Annen, K., Gur, H.D., Hilbert, T. (2023). Head Shot!. In: Immunohematology, Transfusion Medicine, Hemostasis, and Cellular Therapy. Springer, Cham. https://doi.org/10.1007/978-3-031-14638-1_37

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-14638-1_37

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-14637-4

  • Online ISBN: 978-3-031-14638-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation